ArticleMucosal immunology2021
Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
Article in Mucosal immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Targeted C3G delivery by engineered milk exosomes for effective therapy in microplastics-induced colitis.Materials today. Bio · 2026Article
- Gut microbiota metabolites in inflammatory bowel disease: advances in mechanistic insights.Frontiers in immunology · 2026Review
- The Role and Application of MAdCAM-1/α4β7-Induced Lymphocyte Migration in Inflammatory Enterohepatic Diseases.Biomedicines · 2025Review
- Exploring diet-microbiota interactions and therapeutic nutrition management in inflammatory bowel disease.Biophysics reports · 2025Article
- sMAdCAM-1 is decreased after allo-HCT, along with gut microbiota dysbiosis, and is associated with hematopoietic recovery.HemaSphere · 2025Article
- CU06-1004 inhibits the progression of chronic colitis and colitis-associated colorectal cancer by suppressing inflammation.Frontiers in pharmacology · 2025Article
- Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment.Biomedicines · 2024Review
- Exploring potential causal associations between autoimmune diseases and colorectal cancer using bidirectional Mendelian randomization.Scientific reports · 2024Article
- Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Bile acids and their receptors: Potential therapeutic targets in inflammatory bowel disease.World journal of gastroenterology · 2023Review
- Review
- Ursodeoxycholic acid induces sarcopenia associated with decreased protein synthesis and autophagic flux.Biological research · 2023Article
- Therapeutic role of ursodeoxycholic acid in colitis-associated cancer via gut microbiota modulation.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Bile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance.Oncoimmunology · 2023Article
- Intestinal microbiota in the treatment of metabolically associated fatty liver disease.World journal of clinical cases · 2022Review
- Bile acids as inflammatory mediators and modulators of intestinal permeability.Frontiers in immunology · 2022Review
- Article
- Review
- Article
- Microbial-derived indoles inhibit neutrophil myeloperoxidase to diminish bystander tissue damage.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Primary sclerosing cholangitis (PSC) is a progressive fibrosing cholestatic liver disease that is strongly associated with inflammatory bowel disease (IBD). PSC-associated IBD (PSC-IBD) displays a unique phenotype characterized by right-side predominant colon inflammation and increased risk of colorectal cancer compared to non-PSC-IBD. The frequent association and unique phenotype of PSC-IBD suggest distinctive underlying disease mechanisms from other chronic liver diseases or IBD alone. Multidrug resistance protein 2 knockout (Mdr2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.